BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 22858184)

  • 1. High-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and cardiovascular disease in United States adults.
    Bilhorn KR; Luo Y; Lee BT; Wong ND
    Am J Cardiol; 2012 Nov; 110(10):1464-7. PubMed ID: 22858184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of red cell distribution width and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic population: findings from the 1999-2004 NHANES.
    Veeranna V; Zalawadiya SK; Panaich S; Patel KV; Afonso L
    Int J Cardiol; 2013 Oct; 168(6):5156-61. PubMed ID: 24016543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey.
    Miller M; Zhan M; Havas S
    Arch Intern Med; 2005 Oct; 165(18):2063-8. PubMed ID: 16216995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The associations between current recommendation for physical activity and cardiovascular risks associated with obesity.
    Akbartabartoori M; Lean ME; Hankey CR
    Eur J Clin Nutr; 2008 Jan; 62(1):1-9. PubMed ID: 17342166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
    Tóth PP; Potter D; Ming EE
    J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus.
    Nichols GA; Vupputuri S; Rosales AG
    Am J Cardiol; 2011 Oct; 108(8):1124-8. PubMed ID: 21985949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated C-reactive protein associated with decreased high-density lipoprotein cholesterol in men with spinal cord injury.
    Liang H; Mojtahedi MC; Chen D; Braunschweig CL
    Arch Phys Med Rehabil; 2008 Jan; 89(1):36-41. PubMed ID: 18164328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of low HDL cholesterol, and relationship between serum HDL and cardiovascular disease in elderly Spanish population: the PREV-ICTUS study.
    Cea-Calvo L; Lozano JV; Fernández-Pérez C; Llisterri JL; Martí-Canales JC; Aznar J; Gil-Guillén V; Redón J;
    Int J Clin Pract; 2009 Jan; 63(1):71-81. PubMed ID: 19125995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRP level and HDL cholesterol concentration jointly predict mortality in a Korean population.
    Kim KI; Oh SW; Ahn S; Heo NJ; Kim S; Chin HJ; Na KY; Chae DW; Kim CH; Kim S
    Am J Med; 2012 Aug; 125(8):787-95.e4. PubMed ID: 22840665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population: National Health and Nutrition Examination Survey 2005-2008.
    Christian JB; Bourgeois NE; Lowe KA
    J Cardiovasc Med (Hagerstown); 2011 Oct; 12(10):714-22. PubMed ID: 21881447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
    Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.
    Ghandehari H; Kamal-Bahl S; Wong ND
    Am Heart J; 2008 Jul; 156(1):112-9. PubMed ID: 18585505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
    Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
    Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma lipoprotein levels as predictors of cardiovascular death in women.
    Bass KM; Newschaffer CJ; Klag MJ; Bush TL
    Arch Intern Med; 1993 Oct; 153(19):2209-16. PubMed ID: 8215724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study.
    Lozano JV; Pallarés V; Cea-Calvo L; Llisterri JL; Fernández-Pérez C; Martí-Canales JC; Aznar J; Gil-Guillén V; Redón J;
    Curr Med Res Opin; 2008 Mar; 24(3):659-70. PubMed ID: 18218194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma C-reactive protein in subjects with hypo/hyperalphalipoproteinemias.
    Pirro M; Siepi D; Lupattelli G; Roscini AR; Schillaci G; Gemelli F; Vaudo G; Marchesi S; Pasqualini L; Mannarino E
    Metabolism; 2003 Apr; 52(4):432-6. PubMed ID: 12701054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different impacts of C-reactive protein and lipid profile on coronary lesions following a percutaneous coronary intervention.
    Xu HY; Qiao SB; Zhang JF; Dong QT; Li JJ
    Coron Artery Dis; 2012 May; 23(3):181-7. PubMed ID: 22336660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on C-reactive protein and the risk factors of traditional coronary heart disease].
    Guo ZR; Hu XS; Chen FM; Wu M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1064-8. PubMed ID: 18396656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.